MPR

Subcutaneous Lecanemab Starting Dose Under Review for Alzheimer Disease

Previously lecanemab was only approved as an SC injection for maintenance dosing, following an initial 18 month IV phase.

FDA approves first treatment for Menkes disease in children

The U.S. Food and Drug Administration has approved the Zycubo (copper histidinate) injection as the first treatment for ...
pharmaphorum

J&J's subcutaneous Rybrevant cleared by FDA

Johnson & Johnson has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of its EGFRxMET bispecific antibody, for all the indications approved for the current, intravenous formulation.
Oncology Nurse Advisor

FDA Approves Subcutaneous Rybrevant Faspro for EGFR-Mutated Non-Small Cell Lung Cancer

Subcutaneous administration takes less time and is tied to fewer administration-related reactions than intravenous.
Fierce Pharma

GSK licenses Alteogen enzyme in bid to develop subQ Jemperli

With star checkpoint inhibitors like Keytruda and Opdivo now sporting subcutaneous formulations, GSK has struck a deal aimed ...
Neurology Advisor

First Treatment for Menkes Disease: FDA Approves Copper Histidinate

The Food and Drug Administration (FDA) has approved Zycubo® (copper histidinate) for the treatment of Menkes disease in pediatric patients.